# AgBiome Financial Model

AgBiome is a microbial-platform agtech company that discovers, develops, and commercialises biological crop protection products (and licences the platform across adjacent markets).

- Canonical: https://finamodel.com/startups/agbiome
- Excel download: https://finamodel.com/startup-models/agbiome.xlsx
- Category: Enterprise/Security
- Model type: Startup Valuation
- Funding round: Series D
- Funding: $116M
- Founded: 2021
- Geography: Global (US commercial launch of Howler; international partnerships noted).
- Customer: B2B

## About the company

AgBiome discovers and commercialises biological crop-protection products from its Genesis microbial and genomics platform. Its flagship Howler fungicide addresses hundreds of crop-disease combinations, while the underlying platform also supports work in animal health, gene editing, and other adjacent markets.

Revenue comes from wholly owned product sales alongside joint ventures, licence fees, development milestones, and royalties. The company was supported by major ag and life-sciences investors and described a product-launch roadmap extending through 2030.

The model separates each product's launch ramp and gross margin from licence and royalty income by partner. It then links R&D, commercial spending, and cash runway to a probability-weighted pipeline valuation, with scenarios driven by market penetration, launch timing, new licensing agreements, and margin.

## What's included

- 5-year monthly revenue build with stage-appropriate growth assumptions
- Full P&L, headcount plan, and operating-expense schedule
- Cash-flow statement, runway, and burn-rate tracking
- Valuation via exit multiple with a DCF cross-check
- Returns analysis with MOIC and IRR
- Unit economics including CAC, LTV, payback, and cohort retention

## Product & value proposition

- Flagship product: **Howler®** - biological fungicide; works on 300+ crop-disease combinations (Botrytis, Rhizoctonia, Colletotrichum, Alternaria, Pythium, Phytophthora, Powdery/Downy Mildews, Sclerotinia).
- Platform: **Genesis™** - proprietary genomic/informatics platform. 90,000+ fully-sequenced microbe strains (target 1M within 3 years); >300M unique genes; custom ML tools; can compare 100,000+ strains simultaneously or 45,000 genomes/second.
- Value proposition to growers: crop protection / higher yield, resistance management, reduced chemical residues, worker safety, sustainable production.
- Value proposition to consumers: natural/clean food, less chemical exposure, responsibly grown.
- Addresses 12/17 UN SDGs.

## Market

- **Global Biologicals market (primary):** $1.4B (2020) → $14.4B (2030); CAGR ~26%
  - Breakdown 2030: Biological Fungicides $5.8B, Insecticides & Nematicides $3.8B, Herbicides $3.3B, Biostimulants $1.5B.
- **Market share shift:** Biologicals = 2% of total crop protection market (~$60B conventional chemicals) in 2020; projected to reach 14% of ~$100B by 2030.
- **Seven platform markets (TAM stated per market):**
  - Biologicals (wholly owned): $100B TAM
  - Pharma (early licence/spinout): $500B TAM
  - Synthetic Biology (early licence): $200B TAM
  - Gene Editing (JV/early licence): $100B TAM
  - Animal Health (early licence): $50B TAM
  - Ag Traits / JV: $37B TAM
  - Industrial Enzymes (early licence): $20B TAM

## Revenue model

Four distinct business models layered on the same Genesis platform:

| Model | Who owns | Who commercialises | Value created |
| -- | -- | -- | -- |
| Wholly-owned | AgBiome | AgBiome | Revenue, profit, EV (e.g. Howler®, Theia) |
| JV / In-license | Partner | AgBiome | Market access, royalties, revenue, profit, EV |
| Early License | AgBiome | Partner | Early cash payment, royalties, technology leadership |
| Late License | AgBiome | Partner | Royalties, milestones, monetise pipeline |

- Named partnerships: LifeEdit (gene editing), GENECTIVE technology for plants (JV with TMG - Tropical Melhoramento & Genética), Elanco (animal health).
- Distribution: "Support of the largest U.S. ag retailers."

## Traction & metrics

- **Howler® first full year:** "Generated significant revenue in its first full year, expected to grow in 2021 as a standalone product." - no dollar figure disclosed.
- **Demo activity:** ~240 product demos conducted.
- **Retail support:** Supported by the largest U.S. ag retailers.
- **Field performance:** Outperforming conventional products across multiple crops in key value drivers.
- **Pipeline:** Cumulative product launches: 1 (2020) → 3 (2021) → 7 (2022) → 8 (2023) → 10 (2024) → 11 (2025) → 12 (2026) → 16 (2027) → 23 (2028) → 28 (2029) → 30 (2030).

## Competition / moat

- Moat: largest fully-sequenced microbe collection in the world; proprietary Genesis™ informatics platform; broad IP covering the fully-integrated process and products; ML-driven screening at massive scale.
- Market context: Less than 5% of crop protection market uses organic/biological alternatives today - early-mover advantage.
- Named competitive moves (all post-2019 M&A): Syngenta/Valagro, American Vanguard/Agrinos, Nutrien/Actagro, UPL/Arysta, Partners Group/Rovensa, Mitsui/Belchim - validating strategic appetite for biologicals platforms.

## Team & funding ask / use of funds

- **Leadership:**
  - Scott Uknes - Co-CEO; co-founder of multiple Ag companies (Ciba, Athenix)
  - Eric Ward - Co-CEO; 30+ years in Ag and CEO experience (2Blades, Cropsolution, Novartis)
  - Toni Bucci - Commercial Director / COO; 20+ years in Ag (BASF)
  - Gerald Coward - CFO; 20+ years finance in Ag (Driscoll's)
  - Rodrigo Sarria - Research; experienced R&D leader (Dow, BASF)
  - Dan Tomso - Business Development; trait research leader (Athenix)
  - Marijn Dekkers - Chairman; former CEO of Bayer and Thermo Fisher, Chairman Novalis LifeSciences
  - John Flannery - Business Advisor; former CEO of GE
- **Investors (existing):** Polaris Partners, ARCH Venture Partners, Pontifax AgTech, Novalis LifeSciences, Fidelity, Novozymes, Bill & Melinda Gates Foundation, Syngenta, Bayer, UTIMCO, Innovtech Advisors.

---

## Recommended financial model

- **Archetype + why:** Multi-revenue-stream AgBio operating model combining (a) product P&L (wholly-owned product sales), (b) milestone + royalty income schedule, and (c) R&D pipeline NPV optionality. This is an operating company, not an M&A or SPAC deck - use an operating forecast. The combination of product revenue and licence income is most comparable to a specialty pharma / agbio royalty + product model.

- **Forecast horizon & granularity:** 2021–2030 annual (aligns with the company's own 2030 product roadmap); quarterly detail for 2021–2023. Ten-year horizon is justified by the long product launch cadence and the market growth chart that extends to 2030.

- **Key drivers & assumptions:**

| Driver | Value / basis |
| -- | -- |
| Howler® 2021E revenue | $X - not disclosed; first full year with significant revenue |
| Pipeline product launches per year | Per slide 9 roadmap (1→3→7→8→10→11→12→16→23→28→30 cumulative) |
| 2030 global biologicals market | $14.4B |
| Early licence / milestone payments | Lump sums at signing + milestone triggers (e.g. IND filing, regulatory approval) |
| JV royalty income | Based on LifeEdit, GENECTIVE, Elanco partnerships |

- **Scenarios (Base / Bull / Bear - which variables flex):**
  - **Base:** Howler grows ~50% YoY to 2025; 2 new product launches/yr on roadmap schedule; 1 early licence deal/yr; market share ~1.5% of biologicals market by 2030.
  - **Bull:** Market adoption accelerates; 3 licence deals/yr; biologicals market reaches 20% of crop protection by 2030; AgBiome IPO/trade sale by 2025–2026.
  - **Bear:** Howler market penetration slower (20% YoY); product launches delayed 1–2 years; no new licence deals in near-term; biologicals market grows to only $8B by 2030.
  - Key flex variables: Howler revenue ramp, number and size of licensing deals, product launch timing, gross margin.

- **Required sheets / outputs:**
  1. **Assumptions** - all drivers, toggle switches for scenario
  2. **Product Revenue Build** - product-by-product launch schedule (from slide 9) × revenue ramp curve × blended ASP
  3. **Licence / Royalty Income** - early licence payments (cash at signing), milestone payments, royalty stream by partner
  4. **P&L (Income Statement)** - gross profit by segment, R&D, SG&A, EBITDA, net income
  5. **Cash Flow & Runway** - operating + investing CF; cumulative cash burn; runway to next raise
  6. **Pipeline NPV** - probability-weighted NPV of 30-product pipeline at 2030 (real option / rNPV)
  7. **Market Sizing Cross-check** - AgBiome revenue as % of biologicals market by year
  8. **Valuation** - DCF + comps (revenue multiple vs. listed agbio/biotech peers); M&A exit scenario
  9. **Dashboard** - KPIs: cumulative products launched, total revenue, EBITDA margin, cash, market share

## Frequently asked questions

### Is the AgBiome financial model free?

Yes. The AgBiome model is a free Excel download with live formulas.

### Can I change the assumptions?

Yes. The workbook is editable and its live formulas recalculate when assumptions change.